The biology of antihormone failure in breast cancer

Nicholson, Robert Ian, Gee, Julia Margaret Wendy ORCID: https://orcid.org/0000-0001-6483-2015, Knowlden, Janice Mary, McClelland, Richard Andrew, Madden, Tracie-Ann ORCID: https://orcid.org/0000-0001-7880-7873, Barrow, Denise and Hutcheson, Iain Robert 2003. The biology of antihormone failure in breast cancer. Breast Cancer Research and Treatment 80 (S1) , pp. 29-34. 10.1023/A:1025467500433

Full text not available from this repository.

Abstract

Many estrogen receptor-positive breast cancer patients initially respond to treatment with antihormonal agents such as tamoxifen, but remissions are often followed by acquisition of resistance and ultimately disease relapse. The development of a rationale for the effective treatment of tamoxifen-resistant breast cancer requires an understanding of the complex signal transduction mechanisms that contribute towards loss of antiestrogen response. Interactions between estrogen and growth factor signaling pathways have been identified in estrogen-responsive cells that are thought to reinforce their individual cellular effects on growth and gene responses. Increasing evidence indicates that abnormalities occurring in growth factor signaling pathways, notably the epidermal growth factor receptor (EGFR) signaling pathway, could dramatically influence steroid hormone action and may be critical to antihormonal-resistant breast cancer cell growth. Thus, inhibitory agents targeting growth factor receptors, or their intracellular pathway components, may prove clinically beneficial in antihormone refractory disease. One example, gefitinib ('Iressa', ZD1839), an EGFR-tyrosine kinase inhibitor, is an interesting therapeutic option that may provide benefit in the treatment of antihormonal-resistant breast cancer. Rapid progress with pharmacological and molecular therapeutic agents is now being made. Therapies that target growth factor signaling pathways may prevent development of resistance.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
Uncontrolled Keywords:	antihormone resistance - breast cancer - epidermal growth factor receptor - estrogen receptor - fulvestrant - gefitinib - tamoxifen
Publisher:	Springer Verlag
ISSN:	0167-6806
Last Modified:	18 Oct 2022 14:20
URI:	https://orca.cardiff.ac.uk/id/eprint/17185

Citation Data

Cited 51 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item